Table 1.
Distribution of patients with brain metastasis, other metastases (NBrM), and non-metastasis (without metastases) according to molecular subtype of the primary breast tumor.
| Patients (N = 208)a | ||||
|---|---|---|---|---|
| Characteristics | Brain metastases | Non-brain distant metastases | Without metastases | p-Value (χ2-test) |
| N (%) | N (%) | N (%) | ||
| 52 (25.0) | 34 (16.3) | 122 (58.7) | ||
| Molecular subtypes | ||||
| Triple negative | 27 (51.9) | 7 (20.6) | 12 (9.8) | |
| Her2-enriched | 12 (23.1) | 3 (8.8) | 6 (4.9) | |
| Lum/Her2+ | 6 (11.5) | 3 (8.8) | 10 (8.2) | |
| Luminal B | 5 (9.6) | 8 (23.6) | 25 (20.5) | |
| Luminal A | 2 (3.9) | 13 (38.2) | 69 (56.6) | <0.0001 |
aPatients included in these three categories (N = 208/211). Three patients were missing (not suitable for biomarkers assessment).